Form 8-K Spark Therapeutics, Inc. For: Aug 07

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. SYNA
2. ON
3. SPY
4. MU
5. AAPL
6. VEON
7. SPCX
8. DRI
9. ABBV
10. USO

Go back to Form 8-K Spark Therapeutics, Inc. For: Aug 07

Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey

August 7, 2018 3:32 PM EDT

SunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.

Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More

Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen

August 7, 2018 3:31 PM EDT

Cowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.

Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More

Spark Therapeutics (ONCE) PT Lowered to $64 at RBC Capital

August 7, 2018 2:31 PM EDT

RBC Capital lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $75.00) while maintaining a Sector Perform rating.

Analyst Kennen MacKay said the view today's SPK-8011 update suggestive of efficacy and safety below investor expectations and expect the stock to be choppy into ASH data detailing today's update.

... More

Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection

August 7, 2018 9:34 AM EDT

Cantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.

Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More